Georgoulias, Vassilis

Prognostic value of mature MicroRNA-21 and MicroRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR

Markou, A., Tsaroucha, E. G., Kaklamanis, L., Fotinou, M., Georgoulias, V., & Lianidou, E. S. (2008) · Clinical Chemistry

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 441

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F. M., Gebbia, V., Smit, E. F., Morabito, A., Gallo, C., et al. (2009) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 181

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study

Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 113

Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer

McLoed, A. G., Sherrill, T. P., Cheng, D.-S., Han, W., Saxon, J. A., Gleaves, L. A., Wu, P., Polosukhin, V. V., Karin, M., Yull, F. E., et al. (2016) · Cell Reports

NF-κB Signaling PathwaysImmune cells in cancer

Cited by 107

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

Georgoulias, V., Androulakis, N., Kotsakis, A., Hatzidaki, D., Syrigos, K., Polyzos, A., Agelidou, A., Varthalitis, I., Ziras, N., Agelidou, M., et al. (2008) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 44

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

Pallis, A. G., Agelaki, S., Agelidou, A., Varthalitis, I., Syrigos, K., Kentepozidis, N., Pavlakou, G., Kotsakis, A., Kontopodis, E., & Georgoulias, V. (2010) · BMC Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 36